Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Jinxin Fertility (01951.HK) by 513,500 shares on December 30, with a total net reduction of 5.981 million shares over the last five trading days and 15.8205 million shares over the last 20 trading days [1] - As of now, southbound funds hold 1.462 billion shares of Jinxin Fertility, accounting for 53.0% of the company's total issued ordinary shares [1] - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services, along with various medical services and sales of medical consumables and equipment, mainly in China and the United States [1]

Group 1 - Southbound funds increased their holdings in Jinxin Fertility (01951.HK) by 3.07 million shares on December 22 [1] - Over the past 5 trading days, there were 2 days of net reductions totaling 147,500 shares [1] - In the last 20 trading days, there were 11 days of net increases totaling 8.775 million shares [1] Group 2 - As of now, southbound funds hold 1.466 billion shares of Jinxin Fertility, accounting for 53.16% of the company's issued ordinary shares [1] - Jinxin Fertility Medical Group Limited is an investment holding company primarily providing in vitro fertilization (IVF) services [1] - The company offers assisted reproductive services, management services, ambulatory surgical center facility services, auxiliary medical services, obstetrics and pediatrics medical services, as well as sales of medical consumables and equipment, mainly in China and the United States [1]

Core Viewpoint - The "Annual Excellence IR Team (Small and Medium Market Capitalization)" award recognizes outstanding investor relations (IR) teams of listed companies for their significant contributions to industry transformation and development [4]. Group 1: Award Announcement - The "Annual Excellence IR Team (Small and Medium Market Capitalization)" award was presented during the "Technology Empowerment · Capital Breakthrough" sharing session held online by Gelonghui on December 22 [1]. - Ten companies were awarded the "Annual Excellence IR Team (Small and Medium Market Capitalization)" award, including Beikang Medical-B (02170.HK), Gushengtang (02273.HK), Huitongda Network (09878.HK), Jinxin Fertility (01951.HK), Kunbo Medical-B (02216.HK), Lianlian Digital (02598.HK), Qingsi Games (06633.HK), TCL Electronics (01070.HK), Yaxin Technology (01675.HK), and Zhaoke Ophthalmology-B (06622.HK) [1]. Group 2: Evaluation Criteria - The award evaluation focused on the construction of communication channels between IR teams and investors, emphasizing the importance of long-term perspectives on companies' overall performance [4]. - The selection process involved quantitative data analysis and expert review to determine the final results [4]. Group 3: Broader Context - Gelonghui aims to create a reference value ranking of listed companies and unicorns in the investment community, covering all listed companies on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4].

Group 1 - The company, Jinxin Reproductive Medicine (01951.HK), announced a share buyback on December 17, 2023, spending HKD 12.121 million to repurchase 4.825 million shares [1]

Group 1 - The company, Jinxin Reproductive Medicine (01951), announced a share buyback plan on December 17, 2025, involving an expenditure of HKD 12.121 million to repurchase 4.825 million shares [1]

Core Viewpoint - Jinxin Fertility (01951) announced a share buyback plan, intending to repurchase 4.825 million shares for a total cost of HKD 12.121 million [1] Group 1 - The company will execute the buyback on December 17, 2025 [1] - The total number of shares to be repurchased is 4.825 million [1] - The total expenditure for the buyback is HKD 12.121 million [1]

| 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01951 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年12月15日 | | 2,744,706,043 | | 13,000,000 | | 2,757,706,043 | | 1). 其他 (請註明) | | | | % | | | | | 見B部分 | | | | | | | | | 變動日期 | 2025年12月17日 | | | | | ...

Core Insights - The article discusses the stock buyback activities of various companies, highlighting the total amounts and quantities repurchased, with Tencent Holdings leading the buyback efforts [1][2]. Group 1: Buyback Overview - Tencent Holdings (00700) repurchased 1.051 million shares for a total of 636 million, representing 0.995% of its total share capital [2]. - Xiaomi Group (01810) repurchased 7.2 million shares for 302 million, accounting for 0.430% of its total share capital [2]. - China COSCO Shipping Holdings (01919) repurchased 2.95 million shares for 40.016 million, which is 3.089% of its total share capital [2]. Group 2: Notable Buybacks - Kuaishou Technology (01024) repurchased 462,000 shares for 29.9304 million, representing 0.191% of its total share capital [2]. - Kingsoft Corporation (03888) repurchased 702,800 shares for 19.9994 million, which is 0.580% of its total share capital [2]. - Country Garden Services (06098) repurchased 3 million shares for 18.9615 million, accounting for 1.284% of its total share capital [2]. Group 3: Other Companies - Coolpad Group (02369) repurchased 3.16 million shares for 4.1717 million, representing 7.986% of its total share capital [2]. - China Petroleum & Chemical Corporation (00386) repurchased 764,000 shares for 3.306 million, which is 0.190% of its total share capital [2]. - Mengniu Dairy (02319) repurchased 200,000 shares for 2.9675 million, accounting for 0.762% of its total share capital [2].

Group 1 - The company, Jinxin Reproductive Medicine (01951), announced a share buyback plan on December 15, 2025, with an investment of HKD 9.939 million to repurchase 3.891 million shares [1]

Group 1 - The company, Jinxin Reproductive Medicine (01951), announced a share buyback plan on December 15, 2025, involving an expenditure of HKD 9.939 million to repurchase 3.891 million shares [1]